13/2/2024
BIOIATRIKI Healthcare Group, a leader in the field of Primary Health Care, announces the successful completion of the legal process for the acquisition of Pavlidis Laboratories. This marks a significant strategic move that strengthens the Group’s position nationwide, especially in the Limassol and Paphos regions, aiming at further expanding its high-level primary healthcare services to all patients. With the inclusion of Pavlidis Laboratories into the Group, visitors and patients will have access to more than 3,500 clinical laboratory tests. Additionally, the Group’s branches will undergo gradual renovation throughout 2024, aiming to optimize patient experience and service. Mr. George Spanos, CEO of the BIOIATRIKI Healthcare Group, stated: “The strategic investment in the acquisition of Pavlidis Laboratories represents a significant step in the development journey of our company and further strengthens the Group’s presence in Cyprus. By joining forces with Pavlidis Laboratories, we once again demonstrate our commitment to offer even greater value to our patients and to continue innovating, growing, and leading the developments in our industry!” Director of Operations and Business Development of BIOIATRIKI Healthcare Group in Cyprus, Mr. Anastasios Kalogiannis stated: “It is with great joy and pride that we announce the successful acquisition of Pavlidis Laboratories by the BIOIATRIKI Healthcare Group in Cyprus. This strategic move significantly enhances our presence in the Limassol and Paphos regions, offering the residents comprehensive and high-level services and the opportunity to utilize the full range of clinical laboratory tests available through the Group in Greece and Cyprus. With our services becoming increasingly accessible to everyone, without geographic, financial, or other limitations, and always with a commitment to our known belief of development ‘Quality – Reliability – Innovation,’ we renew our promise for continued investments and support for Health in the Republic of Cyprus.” Dr. Stefanos Pavlidis, (Biomedical Scientist), thanked the Group for their trust and selection, emphasizing that through the acquisition of Pavlidis Laboratories, a leading private provider of primary healthcare services in Greece and Cyprus, the absorbed centers will be able to upgrade their services significantly and substantially to the residents of Limassol and Paphos, expanding their diagnostic capabilities and reliability as well as enhancing their quality footprint. BIOIATRIKI Healthcare Group has been active in Cyprus since 2017, having undertaken the establishment, staffing and operation of the clinical laboratory of the German Oncology Center, and the acquisition of the majority of shares of Yiannoukas Medical Laboratories and Alpha Evresis Diagnostic Center. With the addition of Pavlidis Laboratories, the Group will now have in Cyprus 2 accredited clinical laboratories, a radiology center with 2 fully equipped branches and multiple medical devices per category of tests, 25 sampling centers, and the first Polydynamo Diagnostic Center in Nicosia, with the most modern Clinical Laboratory and Radiodiagnostic equipment, including extensive use of automation, multiple innovations with artificial intelligence and radiation reduction software, as well as specialized scientific and medical staff.
